Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells
Abstract
BackgroundHIV eradication strategies are now being evaluated in vitro and in vivo. A cornerstone of such approaches is maximal suppression of viral replication with combination antiretroviral therapy (ART). Since many antiretroviral agents have off target effects, and different classes target different components of the viral life cycle, we questioned whether different classes of ART might differentially affect the survival and persistence of productively HIV-infected CD4 T cells.
MethodsIn vitro infections of primary CD4 T cells using clinical isolates of HIV-1 that were either protease inhibitor susceptible (HIV PI-S), or resistant (HIV PI-R) were treated with nothing, lopinavir, efavirenz or raltegravir. Cell viability, apoptosis, and the proportion of surviving cells that were P24 positive was assessed by flow cytometry.
ResultsIn HIV PI-S infected primary cultures, all three antiretroviral agents decreased viral replication, and reduced the total number of cells that were undergoing apoptosis (P < 0.01) similarly. Similarly, in the HIV PI-R infected cultures, both efavirenz and raltegravir reduced viral replication and reduced apoptosis compared to untreated control (P < 0.01), while lopinavir did not, suggesting that HIV replication drives T cell apoptosis, which was confirmed by association by linear regression (P < 0.0001) . However since HIV protease has been suggested to directly induce apoptosis of infected CD4 T cells, and HIV PI are intrinsically antiapoptotic, we evaluated apoptosis in productively infected (HIV P24+) cells. More HIV p24 positive cells were apoptotic in the Efavirenz or raltegravir treated cultures than the lopinavir treated cultures (P = 0.0008 for HIV PI-R and P = 0.06 for the HIV PI-S), indicating that drug class impacts survival of productively infected CD4 T cells.
ConclusionsInhibiting HIV replication with a PI, NNRTI or INSTI reduces total HIV-induced T cell apoptosis. However, blocking HIV replication with PI but not with NNRTI or INSTI promotes survival of productively HIV-infected cells. Thus, selection of antiretroviral agents may impact the success of HIV eradication strategies.
Downloads
References
Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM: Prospects for treatment of latent HIV. Clin Pharmacol Ther. 2013, 93: 46-56.
PubMedCentralCrossRefPubMedGoogle Scholar
Xing S, Siliciano RF: Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today. 2012, 18 (11-12): 541-551.
PubMedCentralCrossRefPubMedGoogle Scholar
Shan L, Deng K, Shroff NS: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012, 36: 491-501.
PubMedCentralCrossRefPubMedGoogle Scholar
Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V: Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog. 2011, 7: e1002288-
PubMedCentralCrossRefPubMedGoogle Scholar
Deeks SG: HIV: Shock and kill. Nature. 2012, 487: 439-440.
CrossRefPubMedGoogle Scholar
Jain V, Hartogensis W, Bacchetti P: Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013, 208: 1202-1211.
PubMedCentralCrossRefPubMedGoogle Scholar
Graf EH, Mexas AM, Yu JJ: Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV + patients on and off HAART. PLoS Pathog. 2011, 7: e1001300-
PubMedCentralCrossRefPubMedGoogle Scholar
Chun TW, Murray D, Justement JS: Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011, 204: 135-138.
PubMedCentralCrossRefPubMedGoogle Scholar
Hukezalie KR, Thumati NR, Cote HC, Wong JM: In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS One. 2012, 7: e47505-
PubMedCentralCrossRefPubMedGoogle Scholar
Jochmans D, Anders M, Keuleers I: Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology. 2010, 7: 89-
PubMedCentralCrossRefPubMedGoogle Scholar
Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, Badley AD: Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2002, 46: 2687-2691.
PubMedCentralCrossRefPubMedGoogle Scholar
Vlahakis SR, Bren GD, Algeciras-Schimnich A, Trushin SA, Schnepple DJ, Badley AD: Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Clin Pharmacol Ther. 2007, 82: 294-299.
CrossRefPubMedGoogle Scholar
Weaver JG, Rouse MS, Steckelberg JM, Badley AD: Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. Faseb J. 2004, 18: 1185-1191.
CrossRefPubMedGoogle Scholar
Weaver JG, Tarze A, Moffat TC: Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest. 2005, 115: 1828-1838.
PubMedCentralCrossRefPubMedGoogle Scholar
Hisatomi T, Nakazawa T, Noda K: HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest. 2008, 118: 2025-2038.
PubMedCentralPubMedGoogle Scholar
Nie Z, Phenix BN, Lum JJ: HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ. 2002, 9: 1172-1184.
CrossRefPubMedGoogle Scholar
Nie Z, Bren GD, Vlahakis SR: Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol. 2007, 81: 6947-6956.
PubMedCentralCrossRefPubMedGoogle Scholar
Natesampillai S, Nie Z, Cummins NW: Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. PLoS Pathog. 2010, 6: e1001213-
PubMedCentralCrossRefPubMedGoogle Scholar
Dietz AB, Bulur PA, Emery RL: A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 2006, 46: 2083-2089.
CrossRefPubMedGoogle Scholar
Bren GD, Whitman J, Cummins N: Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication. PLoS One. 2008, 3: e2112-
PubMedCentralCrossRefPubMedGoogle Scholar
Markowitz M, Mohri H, Mehandru S: Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet. 2005, 365: 1031-1038.
CrossRefPubMedGoogle Scholar
Pantaleo G, Graziosi C, Fauci AS: New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993, 328: 327-335.
CrossRefPubMedGoogle Scholar
Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD: Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood. 2001, 98: 1078-1085.
CrossRefPubMedGoogle Scholar
Algeciras-Schimnich A, Belzacq-Casagrande AS, Bren GD: Analysis of HIV protease killing through caspase 8 reveals a novel interaction between caspase 8 and mitochondria. Open Virol J. 2007, 1: 39-46.
PubMedCentralPubMedGoogle Scholar
Doyle T, Geretti AM: Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis. 2012, 25: 17-25.
CrossRefPubMedGoogle Scholar
Badley AD, Parato K, Cameron DW: Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 1999, 6: 420-432.
CrossRefPubMedGoogle Scholar
Chavan SJ, Tamma SL, Kaplan M, Gersten M, Pahwa SG: Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol. 1999, 93: 24-33.
CrossRefPubMedGoogle Scholar
Badley AD, Dockrell DH, Algeciras A: In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998, 102: 79-87.
PubMedCentralCrossRefPubMedGoogle Scholar
Hashimoto KI, Tsunoda R, Okamoto M, Shigeta S, Baba M: Stavudine selectively induces apoptosis in HIV type 1-infected cells. AIDS Res Hum Retroviruses. 1997, 13: 193-199.
CrossRefPubMedGoogle Scholar
de Oliveira Pinto LM, Lecoeur H, Ledru E, Rapp C, Patey O, Gougeon ML: Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo and in vitro. Aids. 2002, 16: 329-339.
CrossRefPubMedGoogle Scholar
Benveniste O, Estaquier J, Lelievre JD, Vilde JL, Ameisen JC, Leport C: Possible mechanism of toxicity of zidovudine by induction of apoptosis of CD4+ and CD8+ T-cells in vivo. Eur J Clin Microbiol Infect Dis. 2001, 20: 896-897.
CrossRefPubMedGoogle Scholar
Moretti S, Famularo G, Marcellini S: L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. Antioxid Redox Signal. 2002, 4: 391-403.
CrossRefPubMedGoogle Scholar
Jung N, Lehmann C, Knispel M: Long-term beneficial effect of protease inhibitors on the intrinsic apoptosis of peripheral blood mononuclear cells in HIV-infected patients. HIV Med. 2012, 13 (8): 469-478.
PubMedGoogle Scholar
Doitsh G, Cavrois M, Lassen KG: Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010, 143: 789-801.
PubMedCentralCrossRefPubMedGoogle Scholar
Cummins NW, Badley AD: Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis. 2010, 1: e99-
PubMedCentralCrossRefPubMedGoogle Scholar
Ramratnam B, Ribeiro R, He T: Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr. 2004, 35: 33-37.
CrossRefPubMedGoogle Scholar
Gutierrez C, Diaz L, Vallejo A: Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011, 6: e27864-
PubMedCentralCrossRefPubMedGoogle Scholar
Buzon MJ, Massanella M, Llibre JM: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010, 16: 460-465.
CrossRefPubMedGoogle Scholar
Gutierrez C, Diaz L, Vallejo A: 6th IAS Conference on HIV Pathogecnesis and Treatment. Effect of Intensification with Raltegravir on HIV-1 Latently Infected CD4+ Memory T Cells. Abstract no MOPE084
Google Scholar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
Copyright on any open access article in Molecular and Cellular Therapies published bythe Institute is retained by the author(s). Authors can grant any third party the right to use
the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. Please contact the Office of Molecular and Cellular
Therapies for more information specifically regarding permissions if there are questions.
